Core Viewpoint - Definitive Healthcare, a leader in healthcare market data and analytics, will have its CFO, Casey Heller, present at the 28th Annual Needham Growth Conference on January 14, 2026 [1][2]. Company Overview - Definitive Healthcare specializes in data and analytics focused on the business side of healthcare, aiming to simplify the complex healthcare market and provide insights for strategic decision-making [3].

Group 1 - The article does not provide any specific content related to a company or industry [1]

Group 1 - The article does not provide any specific content related to a company or industry [1]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $60 million, down 4% year-over-year, but at the high end of guidance [4][17] - Adjusted EBITDA was $18.9 million, representing a margin of 32%, which was $2 million above the high end of guidance [4][21] - Unlevered free cash flow for the trailing 12 months was approximately $51 million [5][21] - Adjusted net income was $9.7 million, resulting in $0.07 of non-GAAP earnings per share [17][24] Business Line Data and Key Metrics Changes - Subscription revenues were $58.2 million, also down 4% year-over-year, but showed stabilization quarter-over-quarter [18] - Professional services revenue showed modest growth and was largely in line with expectations [18] - Total customer count remained steady at approximately 2,400, with enterprise customer count increasing to 520, the highest level since Q3 of the previous year [5][6] Market Data and Key Metrics Changes - Renewal rates showed year-over-year improvement, although it remains early to determine if this trend is durable [6][18] - Deferred revenue was $92 million, up 7% year-over-year, indicating a positive trend in customer commitments [22] Company Strategy and Development Direction - The company is focusing on four strategic pillars: differentiated data, seamless integrations, customer success, and digital partnerships [7][12] - There is an emphasis on enhancing data quality and expanding data sources to improve competitive positioning [7][8] - The company is investing in digital engagement and partnerships to drive future growth [13][15] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding the macro environment, noting pressures on renewals but also improvements in operational metrics [54][56] - The company expects Q4 revenue to be between $59-$60 million, reflecting a decrease of 4%-5% compared to the same period last year [24] - For the full year, revenue guidance has been raised to $239-$240 million, indicating a 5% decline year-over-year [25] Other Important Information - The company has repurchased approximately 2 million shares for about $9 million, with $49 million remaining under the share repurchase authorization [22] - The integration of data into customer workflows is seen as critical for improving retention rates [10][11] Q&A Session Summary Question: Competitive takeaway regarding the medical device company - Management noted that there is strength in new logo acquisition and that competitive wins are becoming more common due to the quality of their data and integration capabilities [27][28] Question: Importance of new claims data - Management emphasized that claims data is crucial for product positioning and customer needs, with expectations for incremental growth from new data sources [29][30] Question: Changes in pharma clients' budget allocation - No notable changes were observed in budget allocation among biopharma clients, despite tighter budget constraints [32] Question: Improvements in downsell pressure - Management confirmed that downsell pressure remains isolated within the life sciences space, but renewal rates are improving [34][35] Question: Factors driving agency activations - The effectiveness of data in driving targeted marketing campaigns is leading to increased activations from agencies [37][39] Question: Future growth algorithm - Management indicated that future growth will be driven by both new customer acquisition and expansion within existing customers [46][49] Question: Expectations for renewals in December and January - Management acknowledged the significance of the upcoming renewal period and expressed cautious optimism based on recent improvements [54][58]

Third quarter 2025 earnings presentation November 6, 2025 Cautionary statement regarding forward-looking statements This presentation includes forward-looking statements that reflect our current views with respect to future events and financial performance. Such statements are provided under the "safe harbor" protection of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can generally be iden ...

Financial Performance - Total revenue for Q3 2025 was $60,046,000, a decrease of 4.2% from $62,697,000 in Q3 2024[16] - Gross profit for Q3 2025 was $45,993,000, down from $49,031,000 in Q3 2024, reflecting a gross margin of 76.5%[16] - Net loss for Q3 2025 was $17,792,000, compared to a net loss of $187,824,000 in Q3 2024, indicating a significant reduction in losses[16] - The company reported a basic and diluted net loss per share of $0.14 for Q3 2025, compared to $1.12 for Q3 2024[16] - For the nine months ended September 30, 2025, the net loss was $182,150, compared to a net loss of $506,729 for the same period in 2024, representing a 64% improvement[29] - The company reported a net loss of $9.265 million for the quarter ending March 31, 2025, with total equity at $435.905 million[22] - The company recorded a goodwill impairment charge of $176.5 million during the first quarter of 2025, impacting financial results but not liquidity[140] - The net loss for Q3 2025 was $(17,792) million, or (30)% of revenue, compared to a net loss of $(187.824) million, or (300)% of revenue in Q3 2024[206] Assets and Liabilities - Total assets decreased to $755,527,000 as of September 30, 2025, down from $1,089,389,000 at the end of 2024[14] - Total liabilities decreased to $365,857,000 as of September 30, 2025, compared to $482,195,000 at the end of 2024[14] - The company’s total equity decreased to $389,670,000 as of September 30, 2025, down from $607,194,000 at the end of 2024[14] - Long-term debt as of September 30, 2025, was $158.2 million, down from $229.4 million at the end of 2024, with $75.6 million repaid during the nine months ended September 30, 2025[69] - The company has a $175.0 million term loan facility and a $50.0 million revolving credit facility, with the latter having no outstanding balance as of September 30, 2025[71] Cash Flow and Investments - Cash and cash equivalents increased to $108,317,000 from $105,378,000 at the end of 2024[14] - Net cash provided by operating activities was $51,057 for the nine months ended September 30, 2025, slightly up from $50,061 in 2024[29] - The company reported a net cash used in financing activities of $146,877 for the nine months ended September 30, 2025, compared to $43,381 in 2024[29] - Cash and cash equivalents at the end of the period were $108,317, down from $137,609 at the end of the same period in 2024[29] - The Company’s total cash and cash equivalents, including money market funds, amounted to $28.359 million as of September 30, 2025[95] Revenue Breakdown - Subscription services revenue for the nine months ended September 30, 2025, was $173,733 thousand, down 5.9% from $184,645 thousand in 2024[49] - For the nine months ended September 30, 2025, approximately 97% of revenue was derived from subscription services, totaling $179.987 million, compared to $189.914 million in the same period of 2024[167] - Revenue from related parties was $0.3 million for both the three months ended September 30, 2025, and 2024, showing stability in related party transactions[130] - Revenue decreased by $2.7 million, or 4%, in Q3 2025 compared to Q3 2024, primarily due to lower subscription revenue[186] Expenses and Cost Management - Operating expenses for Q3 2025 totaled $54,681,000, significantly lower than $274,398,000 in Q3 2024, primarily due to reduced goodwill impairment[16] - Total cost of revenue for the nine months ended September 30, 2025, was $43,621 thousand, an increase of 8.8% from $40,047 thousand in 2024[129] - Cost of revenue increased by $0.4 million, or 3%, in Q3 2025, driven by a $1.4 million increase in amortization expense[187] - Operating expenses decreased by $427.1 million, or 56%, in the nine months ended September 30, 2025, largely due to a lower goodwill impairment charge[195] Equity and Shareholder Information - The balance of Class A shares decreased to 103,011,649 shares by September 30, 2025, reflecting a reduction in outstanding shares[22] - The Company repurchased 13.9 million shares of Class A Common Stock for an aggregate purchase price of $49.5 million during the nine months ended September 30, 2025[107] - The Company’s ownership interest in Definitive OpCo was 72.9% as of September 30, 2025, down from 74.3% as of December 31, 2024[101] - The Company’s stock repurchase program authorized up to $100.0 million in share repurchases, effective until December 31, 2025[105] Impairment and Restructuring - The company recorded goodwill impairment charges of $176,531 in 2025, a significant decrease from $591,794 in 2024, indicating improved asset valuation[29] - The company incurred restructuring charges of $0.2 million and $8.0 million for the three and nine months ended September 30, 2024, respectively, related to a workforce reduction of approximately 150 people[66] - Goodwill impairment charge of $176.5 million was recorded in the first quarter of 2025 due to a decline in market capitalization[62] Market Conditions and Future Outlook - Macroeconomic conditions have led to longer deal cycles and increased customer churn, particularly among smaller customers in the Life Sciences market[151] - The company expects a negative revenue growth rate for 2025 relative to 2024 due to macroeconomic challenges and elongating deal cycles[165] - The company anticipates that gross profit margin for 2025 will decrease due to anticipated revenue declines and fixed cost structure[173]

Financial Performance - Revenue for Q3 2025 was $60.0 million, a decrease of 4% from $62.7 million in Q3 2024[5] - Net Loss was $(17.8) million, or (30)% of revenue, compared to $(187.8) million in Q3 2024, which included goodwill impairment charges of $228.2 million[5] - Adjusted EBITDA was $18.9 million, or 32% of revenue, compared to $20.6 million, or 33% of revenue in Q3 2024[5] - Adjusted Net Income was $9.7 million, down from $15.4 million in Q3 2024[5] - Gross profit for Q3 2025 was $45,993,000, down from $49,031,000 in Q3 2024, reflecting a decline of 6.3%[33] - Operating expenses for Q3 2025 totaled $54,681,000, significantly lower than $274,398,000 in Q3 2024, indicating a reduction in costs[33] - The company reported a basic and diluted net loss per share of $0.14 for Q3 2025, an improvement from a loss of $1.12 per share in Q3 2024[33] - For the three months ended September 30, 2025, the net loss was $17,792 thousand, compared to a net loss of $187,824 thousand for the same period in 2024[35] - Adjusted Net Income for the three months ended September 30, 2025, was $9,673 thousand, down from $15,393 thousand in 2024, resulting in an Adjusted Net Income Per Diluted Share of $0.07 compared to $0.10[39] - The company reported a gross profit of $45,993 thousand for the three months ended September 30, 2025, representing a gross margin of 77%, compared to $49,031 thousand and 78% in 2024[40] - Unlevered Free Cash Flow for the three months ended September 30, 2025, was $17,941 thousand, down from $24,299 thousand in 2024[37] - Adjusted EBITDA for the nine months ended September 30, 2025, was $52,311,000, with a margin of 29%, down from $61,557,000, or 32%, in the same period of 2024[42] Cash Flow and Liquidity - Cash Flow from Operations was $15.7 million in the quarter[5] - Unlevered Free Cash Flow was $17.9 million in the quarter[5] - Net cash provided by operating activities for the nine months ended September 30, 2025, was $51,057 thousand, slightly up from $50,061 thousand in 2024[37] - Total cash and cash equivalents at the end of the period were $108,317 thousand, compared to $137,609 thousand at the end of the same period in 2024[35] - The company reported capital expenditures of $2,281 thousand for the three months ended September 30, 2025, compared to $767 thousand in 2024[37] - The company had a net cash used in financing activities of $12,471 thousand for the three months ended September 30, 2025, compared to $12,065 thousand in 2024[37] Assets and Liabilities - Total assets decreased to $755,527,000 as of September 30, 2025, down from $1,089,389,000 at December 31, 2024[31] - Total liabilities were $365,857,000 as of September 30, 2025, a decrease from $482,195,000 at December 31, 2024[31] - Cash and cash equivalents increased to $108,317,000 from $105,378,000, reflecting a slight growth of 1.8%[31] - Class A Common Stock outstanding decreased to 103,011,649 shares as of September 30, 2025, down from 113,953,554 shares at December 31, 2024[31] - Total equity decreased to $389,670,000 as of September 30, 2025, down from $607,194,000 at December 31, 2024[31] Impairment and Expenses - The company incurred a Goodwill impairment charge of $228,153 thousand in the three months ended September 30, 2024, which significantly impacted the net loss for that period[39] - Goodwill impairment charges for the nine months ended September 30, 2025, amounted to $176,531,000, representing 98% of the total, compared to $591,794,000, or 312%, in the same period of 2024[44] - The company recognized transaction, integration, and restructuring expenses paid in cash amounting to $547 thousand for the three months ended September 30, 2025[38] - The company incurred total transaction, integration, and restructuring expenses of $7,245,000 for the nine months ended September 30, 2025, compared to $9,390,000 in the same period of 2024[45] - The integration costs for the nine months ended September 30, 2025, were $6,046,000, compared to $939,000 in the same period of 2024[45] Market Position and Future Outlook - For Q4 2025, revenue is expected to be in the range of $59.0 – $60.0 million[11] - Full Year 2025 revenue is expected to be in the range of $239.0 – $240.0 million, raising the bottom end of the prior range by $2.0 million[11] - Adjusted EBITDA for Full Year 2025 is expected to be in the range of $68.0 – $69.0 million, with an adjusted EBITDA margin of 28 – 29%[11] - The company secured new customer wins, including a large multi-national biopharma and a medical device company, enhancing its market position[6] Other Expenses - The company recognized a provision for income taxes of $524,000 for the three months ended September 30, 2025, which is 1% of revenue, compared to a benefit of $(13,724,000), or (22)%, in the same period of 2024[42] - The company reported interest expense of $1,331,000 for the three months ended September 30, 2025, which is 2% of revenue, compared to $7,000, or 0%, in the same period of 2024[42] - Non-core legal and regulatory expenses for the three months ended September 30, 2025, totaled $340,000, compared to $363,000 in the same period of 2024[47] - Equity-based compensation for the three months ended September 30, 2025, was $6,684,000, accounting for 11% of revenue, compared to $6,296,000, or 10%, in the same period of 2024[42] Market Capitalization - The company experienced a decline in market capitalization, triggering goodwill impairment tests, resulting in significant impairment charges[44]

Core Insights - Definitive Healthcare reported third quarter results that met or exceeded the high end of their guidance, with Adjusted EBITDA surpassing expectations by $2 million [3] - The company is focused on operational initiatives and investments to enhance performance over time, showing improvements in new customer acquisition and retention rates [3] Financial Highlights - Revenue for Q3 2025 was $60.0 million, a decrease of 4% from $62.7 million in Q3 2024 [6] - Net loss was $(17.8) million, or (30)% of revenue, compared to $(187.8) million in Q3 2024, which included goodwill impairment charges of $228.2 million [6] - Adjusted Net Income was $9.7 million, down from $15.4 million in Q3 2024 [6] - Adjusted EBITDA was $18.9 million, or 32% of revenue, compared to $20.6 million, or 33% of revenue in Q3 2024 [6] Business and Operating Highlights - The company secured new customer wins across all end-markets, providing critical data and insights [4][7] - A large multi-national biopharma selected Definitive Healthcare to enhance their medical affairs operations, demonstrating the value of their Key Opinion Leader datasets [7] - A medical device company transitioned to Definitive Healthcare after their previous provider failed to deliver necessary insights, highlighting the company's competitive advantage [7] Guidance and Outlook - For Q4 2025, revenue is expected to be in the range of $59.0 – $60.0 million, with Adjusted Operating Income anticipated between $13.5 – $14.5 million [8] - Adjusted EBITDA is projected to be in the range of $16.0 – $17.0 million, with an adjusted EBITDA margin of 27 – 29% [8] - Full year 2025 revenue is expected to be between $239.0 – $240.0 million, raising the bottom end of the prior range by $2.0 million [15]

Core Insights - Definitive Healthcare Corp. will report its financial results for Q3 2025 on November 6, 2025, after market close [1] - A conference call and webcast will be held at 5:00 PM (ET) to discuss the financial results [1] Company Overview - Definitive Healthcare aims to transform data, analytics, and expertise into healthcare commercial intelligence [3] - The company provides SaaS products and solutions to help clients identify market opportunities and achieve commercial success in the healthcare sector [3]

Core Insights - Salubrum has launched a commercialization engine for healthcare growth, utilizing an AI-first approach to automate traditional marketing agency functions [1][6] - The company aims to redefine patient activation in healthcare by partnering with Definitive Healthcare to enhance market strategies for healthcare brands [1][7] Company Background - Founded by Osama Usmani, Salubrum initially focused on medical tourism but pivoted to address commercialization challenges in healthcare [3] - The company identified that healthcare providers were not inaccessible but rather invisible to patients, prompting the development of a new connection model [3] Patient Acquisition Strategy - Salubrum's AI engine addresses the difficulties healthcare providers face in acquiring patients online by filtering out low-quality search results and unsafe options [4] - The goal is to connect healthcare providers with high-intent patients, thereby building trust and improving access [4][5] Vertical Specialization - Salubrum emphasizes true vertical specialization, with its AI tailored to the unique rules, compliance, and KPIs of the healthcare sector [6] - The company aims to automate agency functions and disrupt legacy models through data-driven solutions [6][7] Market Positioning - Salubrum's vertical AI solution is designed to replace traditional agencies in the healthcare industry, supported by strategic partnerships and investments [7][10] - The company has achieved $60,000 in Annual Recurring Revenue (ARR) and a valuation of $2 million [7] Future Vision - Salubrum is focused on creating a new category of brand growth in healthcare marketing, enabling businesses to automate workflows and outperform traditional agencies [8] - The proprietary datasets used by Salubrum allow for true 1:1 programmatic advertising, making high-quality marketing accessible to small and medium enterprises (SMEs) [8][9] Company Support and Backing - Salubrum is backed by Forum Ventures and supported by NEXT Canada and Artest Management Group [10]